Business from biotechs remains down and large pharma’s focus on cost cutting is squeezing suppliers but overall the industry is healthier than it was 12 months ago.
This has led companies to adopt a reservedly optimistic outlook for the year ahead. Whatever the financial situation, the establishment of strong working relationships and provision of quality, on time services continue to be vital for growing business.
India, China and other emerging markets are making gains in this area but still have work to do.